Home Cart Sign in  
Chemical Structure| 3424-98-4 Chemical Structure| 3424-98-4

Structure of Telbivudine
CAS No.: 3424-98-4

Chemical Structure| 3424-98-4

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

Telbivudine selectively inhibits hepatitis B virus (HBV) reverse transcriptase and is used in the treatment of hepatitis B infection.

Synonyms: NV 02B; Epavudine; Tyzeka

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of Telbivudine

CAS No. :3424-98-4
Formula : C10H14N2O5
M.W : 242.23
SMILES Code : O=C1NC(C(C)=CN1[C@H]2O[C@@H](CO)[C@H](O)C2)=O
Synonyms :
NV 02B; Epavudine; Tyzeka
MDL No. :MFCD02683612
InChI Key :IQFYYKKMVGJFEH-CSMHCCOUSA-N
Pubchem ID :159269

Safety of Telbivudine

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302
Precautionary Statements:P280-P305+P351+P338

Isoform Comparison

Biological Activity

In Vitro:

Cell Line
Concentration Treated Time Description References
Endothelial colony-forming cells (ECFC) 10 ng/mL (41.3 nM) 2 hours Telbivudine pretreatment significantly reduced B19V-induced active caspase-3 protein expression (39% reduction) and reversed B19V-induced downregulation of BIRC3 mRNA. PMC6466312
Murine fibroblasts 10 ng/mL 24 hours To evaluate the effect of telbivudine on transforming growth factor-β1 (TGF-β1)-induced oxidative stress. Results showed that telbivudine reduced TGF-β1-induced oxidative stress. PMC6165949
HL-1 cardiomyocytes 10 ng/mL 24 hours To evaluate the effect of telbivudine on angiotensin II (Ang II)-induced oxidative stress. Results showed that telbivudine reduced Ang II-induced oxidative stress and cardiomyocyte hypertrophy. PMC6165949
UT7/EPO S1 cells 10 ng/mL 24 hours To evaluate the effect of telbivudine on B19V-infected UT7/EPO S1 cells. Results showed that telbivudine slightly reduced B19V cDNA expression but did not significantly affect B19V copy number. PMC6165949
Human microvascular endothelial cells-1 (HMEC-1) 10 ng/mL 24 hours To evaluate the endothelial-protective potential of telbivudine in B19V-infected endothelial cells. Results showed that telbivudine reduced B19V-induced endothelial cell apoptosis and endothelial-to-mesenchymal transition (EndMT), and decreased the expression of transforming growth factor-β1 (TGF-β1) and tenascin-C. PMC6165949

Clinical Trial:

NCT Number Conditions Phases Recruitment Completion Date Locations
NCT00781105 Chronic Hepatitis B PHASE4 COMPLETED 2010-09-16 Novartis Investigative Site, B... More >>eijing, China Less <<
NCT03778567 Hepatitis B, Chronic|Chronic K... More >>idney Diseases Less << PHASE4 COMPLETED 2018-05-31 Department of Medicine, The Un... More >>iversity of Hong Kong, Queen Mary Hospital, Hong Kong, Hong Kong Less <<
NCT01637844 HBV PHASE4 COMPLETED 2025-10-14 Nanjing Drum Tower Hospital, N... More >>anjing, Jiangsu, 210008, China|Taixing People's Hospital, Taixing, Jiangsu, 225400, China|Zhenjiang Fourth People's Hospital, Zhenjiang, Jiangsu, 212001, China Less <<
NCT00646503 Hepatitis B, Chronic PHASE4 COMPLETED 2025-09-09 Novartis Investigative Site, B... More >>eijing, China Less <<
NCT00970216 Chronic Hepatitis B COMPLETED 2025-01-16 Chang Gung Memorial Hospital, ... More >>LinKou, Taoyuan County, Taiwan Less <<
NCT00537537 Hepatitis B, Chronic PHASE4 COMPLETED - Novartis Investigative Site, H... More >>yderabad, India|Novartis Investigative Site, Mumbai, India|Novartis Investigative Site, Vellore, India Less <<
NCT01480492 HBeAg Positive Chronic Hepatit... More >>is B Infection Less << COMPLETED 2025-10-11 Changhai Hospital, Shanghai, S... More >>hanghai, 200433, China Less <<
NCT02049736 Chronic Hepatitis B WITHDRAWN 2025-06-15 Cheng Suen Man Shook Hepatitis... More >> Center, Institute of Digestive Disease, The Chinese University of Hong Kong, Prince of Wales Hospital, Hong Kong, Hong Kong Less <<

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

4.13mL

0.83mL

0.41mL

20.64mL

4.13mL

2.06mL

41.28mL

8.26mL

4.13mL

References

 

Historical Records

Categories